A healthcare-dedicated investment firm founded in 2015 with offices in USA has 4 active investment vehicles that allow them to work with companies across various stages of development including private equity, long/short hedge fund, crossover venture fund, and SPAC.
In terms of early-stage opportunities, the firm allocates a few million dollars as initial investment (at a minimum), amount varying on a deal-by-deal basis, and is capable of investing up to $50M over the company’s lifecycle. The firm is open to North American and European opportunities.
The firm is interested in therapeutics, medical devices, tools, labs/diagnostics, and pharmaceutical services. The firm is opportunistic in terms of subsectors and will consider all things healthcare.
The firm prefers to work with management teams that have entrepreneurial experience. The business must show strong potential, and either be revenue-generating or have visibility to approach positive revenue in the next 12-24 months. The company should be built around strong and distinguishable IP that presents a significant market opportunity.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply